{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:02:12Z","timestamp":1790996532812,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001349","name":"Singapore National Medical Research Council","doi-asserted-by":"crossref","award":["CNIG\/1165\/2017"],"award-info":[{"award-number":["CNIG\/1165\/2017"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001349","name":"Singapore National Medical Research Council","doi-asserted-by":"crossref","award":["TCR12dec010"],"award-info":[{"award-number":["TCR12dec010"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001349","name":"Singapore National Medical Research Council","doi-asserted-by":"crossref","award":["MOH-TA18may-0003"],"award-info":[{"award-number":["MOH-TA18may-0003"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001349","name":"Singapore National Medical Research Council","doi-asserted-by":"crossref","award":["NMRC\/STaR\/014\/2013"],"award-info":[{"award-number":["NMRC\/STaR\/014\/2013"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The main motor subtypes of Parkinson\u2019s disease (PD) include tremor-dominant (TD) and postural instability gait disorder (PIGD), with varying disease course that warrant the development of biomarkers capable of predicting progression according to motor subtype. The PIGD subtype is associated with a poorer prognosis, hence identification of a biomarker associated with PIGD is clinically relevant. Neurofilament light (NfL) chain is a potential biomarker of disease severity in neurological disorders including PD. However, no study has investigated NfL and PD motor subtypes. Here, we aimed to investigate the diagnostic and prognostic utility of plasma NfL for PD motor subtypes in early Parkinson\u2019s disease. Given the higher risk for cognitive and motor decline in PIGD, we hypothesized that plasma NfL is a potential biomarker for PIGD.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Plasma NfL was measured in 199 participants (149 PD and 50 healthy controls, HC) using an ultrasensitive single molecule array. Patients were classified into TD or PIGD based on MDS-UPDRS components. After 2\u2009years, 115 patients were reassessed. Association between NfL and clinical measures in PIGD and TD at baseline and at 2-year follow-up were analysed.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>At baseline, plasma NfL levels were higher in PD than HC (8.8\u2009\u00b1\u20093.4 vs 16.2\u2009\u00b1\u20097.6\u2009pg\/ml, <jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.0001), and differentiated PD from HC with a good diagnostic accuracy (AUC\u2009=\u20090.833, <jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.001). At 2\u2009years, NfL was higher in PIGD than TD (18.4\u2009\u00b1\u200914.5 vs 12.6\u2009\u00b1\u20094.4\u2009pg\/ml, <jats:italic>p<\/jats:italic>\u00a0=\u20090.039). Within the PIGD group, higher NfL associated significantly with worse global cognition and UPDRS motor scores at baseline, and was able to predict motor and cognitive decline at a mean follow-up duration of 1.9\u2009years, controlled for age, sex and disease duration.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In this longitudinal study, we demonstrated for the first time the potential utility of plasma NfL as a diagnostic and prognostic biomarker in PIGD even at early stages of PD. These important novel findings will require further confirmation in larger, longitudinal PD cohorts.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13024-020-00385-5","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T20:02:46Z","timestamp":1591387366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson\u2019s disease"],"prefix":"10.1186","volume":"15","author":[{"given":"Adeline Su Lyn","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Jayne","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa Cui Wen","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Ehsan","family":"Saffari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebonne Yulin","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Yong Ern","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole Shuang Yu","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dede","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shermyn","family":"Neo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole Chwee Har","family":"Keong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay Yaw","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Lok","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis Chew Seng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eng-King","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"385_CR1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577.","journal-title":"Nat Rev Neurol"},{"key":"385_CR2","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto G, Barro C, Benkert P, et al. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81:857\u201370.","journal-title":"Ann Neurol"},{"key":"385_CR3","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1212\/WNL.0000000000004029","volume":"88","author":"K Poesen","year":"2017","unstructured":"Poesen K, De Schaepdryver M, Stubendorff B, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88:2302\u20139.","journal-title":"Neurology."},{"key":"385_CR4","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1001\/jamaneurol.2016.5398","volume":"74","author":"A Gaiani","year":"2017","unstructured":"Gaiani A, Martinelli I, Bello L, et al. Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: Neurofilament light chain levels in definite subtypes of disease. JAMA Neurol. 2017;74:525\u201332.","journal-title":"JAMA Neurol."},{"key":"385_CR5","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1212\/WNL.0000000000003154","volume":"87","author":"JD Rohrer","year":"2016","unstructured":"Rohrer JD, Woollacott IOC, Dick KM, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016;87:1329\u201336.","journal-title":"Neurology"},{"key":"385_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/acn3.290","volume":"3","author":"JC Rojas","year":"2016","unstructured":"Rojas JC, Karydas A, Bang J, et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol. 2016;3:216\u201325.","journal-title":"Ann Clin Transl Neurol"},{"key":"385_CR7","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1212\/WNL.0000000000003912","volume":"88","author":"P Shahim","year":"2017","unstructured":"Shahim P, Zetterberg H, Tegner Y, Blennow K. Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology. 2017;88:1788\u201394.","journal-title":"Neurology"},{"key":"385_CR8","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1212\/WNL.0000000000004645","volume":"89","author":"T Gattringer","year":"2017","unstructured":"Gattringer T, Pinter D, Enzinger C, et al. Serum neurofilament light is sensitive to active cerebral small vessel disease. Neurology. 2017;89:2108\u201314.","journal-title":"Neurology."},{"key":"385_CR9","doi-asserted-by":"publisher","unstructured":"Mollenhauer B, Dakna M, Liu T-Y, et al. Validation of serum neurofilament light chain as a biomarker of parkinson\u2019s disease progression. bioRxiv. Cold Spring Harbor Laboratory; Epub. 2019:762237. https:\/\/doi.org\/10.1101\/762237.","DOI":"10.1101\/762237"},{"key":"385_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/mds.27897","volume":"35","author":"LP Oosterveld","year":"2020","unstructured":"Oosterveld LP, Verberk IMW, Majbour NK, et al. CSF or serum neurofilament light added to \u03b1-Synuclein panel discriminates Parkinson\u2019s from controls. Mov Disord. 2020;35:288\u201395.","journal-title":"Mov Disord"},{"key":"385_CR11","doi-asserted-by":"publisher","unstructured":"Hansson O, Janelidze S, Hall S, et al. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017 Mar 7; 88(10):930\u2013937 https:\/\/doi.org\/10.1212\/WNL.0000000000003680.","DOI":"10.1212\/WNL.0000000000003680"},{"key":"385_CR12","doi-asserted-by":"publisher","first-page":"e1479","DOI":"10.1212\/WNL.0000000000007179","volume":"92","author":"TM Marques","year":"2019","unstructured":"Marques TM, van Rumund A, Oeckl P, et al. Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology. 2019;92:e1479\u201386.","journal-title":"Neurology."},{"key":"385_CR13","doi-asserted-by":"publisher","unstructured":"Lin C-H, Li C-H, Yang K-C, et al. Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology. 2019 Sep 10;93(11):e1104-e1111. https:\/\/doi.org\/10.1212\/WNL.0000000000008088. Epub 2019 Aug 16.","DOI":"10.1212\/WNL.0000000000008088"},{"key":"385_CR14","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1212\/WNL.0000000000002768","volume":"86","author":"JF van der Heeden","year":"2016","unstructured":"van der Heeden JF, Marinus J, Martinez-Martin P, Rodriguez-Blazquez C, Geraedts VJ, van Hilten JJ. Postural instability and gait are associated with severity and prognosis of Parkinson disease. Neurology. 2016;86:2243\u201350.","journal-title":"Neurology"},{"key":"385_CR15","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s10072-018-3522-z","volume":"39","author":"D Aleksovski","year":"2018","unstructured":"Aleksovski D, Miljkovic D, Bravi D, Antonini A. Disease progression in Parkinson subtypes: the PPMI dataset. Neurol Sci. 2018;39:1971\u20136.","journal-title":"Neurol Sci"},{"key":"385_CR16","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/mds.27665","volume":"34","author":"Y Guo","year":"2019","unstructured":"Guo Y, Xu W, Liu F-T, et al. Modifiable risk factors for cognitive impairment in Parkinson\u2019s disease: a systematic review and meta-analysis of prospective cohort studies. Mov Disord. 2019;34:876\u201383.","journal-title":"Mov Disord"},{"key":"385_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/archneur.56.1.33","volume":"56","author":"DJ Gelb","year":"1999","unstructured":"Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33\u20139.","journal-title":"Arch Neurol"},{"key":"385_CR18","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/mds.10473","volume":"18","author":"Movement Disorder Society Task Force on Rating Scales for Parkinson\u2019s Disease","year":"2003","unstructured":"Movement Disorder Society Task Force on Rating Scales for Parkinson\u2019s Disease. The unified Parkinson\u2019s disease rating scale (UPDRS): status and recommendations. Mov Disord. 2003;18:738\u201350.","journal-title":"Mov Disord"},{"key":"385_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427\u201342.","journal-title":"Neurology"},{"key":"385_CR20","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mds.25383","volume":"28","author":"GT Stebbins","year":"2013","unstructured":"Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability\/gait difficulty groups with the movement disorder society unified Parkinson\u2019s disease rating scale: comparison with the unified Parkinson\u2019s disease rating scale. Mov Disord. 2013;28:668\u201370.","journal-title":"Mov Disord"},{"key":"385_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398.","journal-title":"J Psychiatr Res"},{"key":"385_CR22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"385_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.parkreldis.2018.06.025","volume":"56","author":"GW O\u2019Keeffe","year":"2018","unstructured":"O\u2019Keeffe GW, Sullivan AM. Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2018;56:9\u201315.","journal-title":"Parkinsonism Relat Disord"},{"key":"385_CR24","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.celrep.2016.05.022","volume":"15","author":"L Lin","year":"2016","unstructured":"Lin L, G\u00f6ke J, Cukuroglu E, Dranias MR, VanDongen AMJ, Stanton LW. Molecular features underlying Neurodegeneration identified through in vitro modeling of genetically diverse Parkinson\u2019s disease patients. Cell Rep. 2016;15:2411\u201326.","journal-title":"Cell Rep"},{"key":"385_CR25","first-page":"1277","volume":"70","author":"J-H Kang","year":"2013","unstructured":"Kang J-H, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid \u03b2-amyloid 1-42, T-tau, P-tau181, and \u03b1-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 2013;70:1277\u201387.","journal-title":"JAMA Neurol"},{"key":"385_CR26","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00401-016-1552-2","volume":"131","author":"J-H Kang","year":"2016","unstructured":"Kang J-H, Mollenhauer B, Coffey CS, et al. CSF biomarkers associated with disease heterogeneity in early Parkinson\u2019s disease: the Parkinson\u2019s progression markers initiative study. Acta Neuropathol. 2016;131:935\u201349.","journal-title":"Acta Neuropathol"},{"key":"385_CR27","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/mds.27232","volume":"33","author":"JG Goldman","year":"2018","unstructured":"Goldman JG, Andrews H, Amara A, et al. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: relationships among biomarkers and Parkinson\u2019s disease features. Mov Disord. 2018;33:282\u20138.","journal-title":"Mov Disord"},{"key":"385_CR28","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00702-016-1650-2","volume":"124","author":"J Ding","year":"2017","unstructured":"Ding J, Zhang J, Wang X, et al. Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson\u2019s disease. J Neural Transm (Vienna). 2017;124:353\u201360.","journal-title":"J Neural Transm (Vienna)"},{"key":"385_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.parkreldis.2018.05.010","volume":"55","author":"X Huang","year":"2018","unstructured":"Huang X, Ng SY-E, Chia NS-Y, et al. Serum uric acid level and its association with motor subtypes and non-motor symptoms in early Parkinson\u2019s disease: PALS study. Parkinsonism Relat Disord. 2018;55:50\u20134.","journal-title":"Parkinsonism Relat Disord"},{"key":"385_CR30","doi-asserted-by":"publisher","unstructured":"De Pablo-Fern\u00e1ndez E, Lees AJ, Holton JL, Warner TT. Prognosis and Neuropathologic correlation of clinical subtypes of Parkinson disease. JAMA Neurol. 2019 Apr 1;76(4):470\u201379. https:\/\/doi.org\/10.1001\/jamaneurol.2018.4377.","DOI":"10.1001\/jamaneurol.2018.4377"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-020-00385-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-020-00385-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-020-00385-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T23:18:44Z","timestamp":1622848724000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-020-00385-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["385"],"URL":"https:\/\/doi.org\/10.1186\/s13024-020-00385-5","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"assertion":[{"value":"13 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was obtained from the Singapore Health Services Centralised Institutional Review Board (CIRB) for the use of human participants in this study, and all participants provided informed written consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved of the manuscript and agree with its submission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}